Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC)
In: Journal of Clinical Oncology, Jg. 22 (2004-07-15), S. 4657-4657
Online
unknown
Zugriff:
4657 Background: DHA-paclitaxel (Taxoprexin) is a covalent conjugate of paclitaxel and docosahexaenoic acid that has greater tumor specificity in pre-clinical models than paclitaxel. The conjugate accumulates in tumor tissue where it is cleaved to paclitaxel. The objective of this multi-center study was to evaluate the efficacy and tolerability of TXP as first line therapy in patients with HRPC. Methods: Thirty-six patients, median age 70y (range 56–86) PS 0 (12), PS 1 (24) with advanced HRPC and no previous cytotoxic treatment were enrolled. Patients were required to have adequate renal, hepatic and bone marrow function and measurable disease. TXP was administered iv over 2 hours q21 days at one of two doses, 1100 mg/m2 (14), 900 mg/m2 (22) . Results: Fifty-one courses (mean 3.6) were administered at 1100 mg/m2 and 65 courses (mean 2.9) at 900 mg/m2. Neutropenia was the primary toxicity and was dose limiting: 12 of 14 (86%) patients treated at 1100 mg/m2 had grade 3/4 neutropenia vs. 9 of 22 (41%) at 900...
Titel: |
Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC)
|
---|---|
Autor/in / Beteiligte Person: | Mansour, R. ; Modiano, M. ; Petrylak, Daniel P. ; Carducci, M. ; Bellet, R. ; Axelrod, R. ; Irwin, D. ; Doukas, M. ; Kasimis, B. |
Link: | |
Zeitschrift: | Journal of Clinical Oncology, Jg. 22 (2004-07-15), S. 4657-4657 |
Veröffentlichung: | American Society of Clinical Oncology (ASCO), 2004 |
Medientyp: | unknown |
ISSN: | 1527-7755 (print) ; 0732-183X (print) |
DOI: | 10.1200/jco.2004.22.90140.4657 |
Schlagwort: |
|
Sonstiges: |
|